Harbor Capital Advisors shares Q2 updates on its Health Care ETF, spotlighting biotech gains, policy risks, and M&A potential ...

Pfizer (PFE), a pharmaceutical and biotechnology company, rose to great heights during the pandemic with its COVID-19 vaccine ...

Special Report: LTR Pharma has co-founded and secured a 33% equity ownership in LevOmega, an Australian company focused on ...

Eupraxia Pharmaceuticals Inc. ('Eupraxia” or the 'Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize ...

An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. On September 22, 2025, Eupraxia Pharmaceuticals announced a proposed ...

Innovative AI-powered monitoring enables a leading pharmaceutical and biotechnology company to optimize transport modes without compromising product integrity ...

A new training space for future biopharmaceutical employees is now operational at the Pitt County Technology Enterprise ...

French biopharma Genfit has announced its decision to discontinue its VS-01 program in acute-on-chronic liver failure (ACLF) ...

Metsera, which went public in January this year, could provide Pfizer with strong growth drivers in the obesity treatment ...

Verrica CEO Jayson Rieger said a $10 million payment from its licensing partner will immediately strengthen the firm's ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

Pfizer has sealed an up to $7.3bn takeover of weight-loss drug developer Metsera in the biggest deal yet by a large pharmaceutical group trying to gain a foothold in the lucrative market.